Remove tag real-world-science
article thumbnail

Grand Rounds October 28, 2022: The HERO (Healthcare Worker Exposure Response & Outcomes) Program: An Online Community to Support Observational Studies, Randomized Trials, and Long-Term Safety Surveillance (Emily O’Brien, PhD, FAHA; Russell Rothman, MD, MPP)

Rethinking Clinical Trials

Department of Population Health Sciences. The HERO TOGETHER study leveraged the HERO Registry to estimate real-world incidence of safety events among vaccinated individuals. ? ? ? ? ? ?. Speakers. Emily O’Brien, PhD, FAHA. Associate Professor. Duke Clinical Research Institute. Duke University School of Medicine.

Trials 130
article thumbnail

Grand Rounds Ethics and Regulatory Series November 11, 2022: Data Sharing and Pragmatic Clinical Trials: Law & Ethics Amidst a Changing Policy Landscape (Stephanie Morain, PhD, MPH; Kayte Spector-Bagdady, JD, MBioethics)

Rethinking Clinical Trials

Associate Director, Center for Bioethics & Social Sciences in Medicine. clinicians, health systems), data may have been collective for administrative/clinical purposes, data may be more representative of “real world” conditions, and data may be controlled by a third party (e.g. Kayte Spector-Bagdady, JD, MBioethics.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds August 18, 2023: Opportunities to Improve Clinical Trials: Draft Revision of the ICH Good Clinical Practice Guideline (E6R3) (Prof Sir Martin Landray, FMedSci; M. Khair ElZarrad, PhD, MPH)

Rethinking Clinical Trials

The rapidly evolving ecosystem now relies on real-world data, which is becoming increasingly more advanced, and clinical trial design is becoming more complex and innovative. Annex-2 of E6(R3) will include additional considerations of GCP principles focused on decentralized elements, pragmatic elements and real-world data sources.

article thumbnail

Grand Rounds August 18, 2023: Opportunities to Improve Clinical Trials: Draft Revision of the ICH Good Clinical Practice Guideline (E6R3) (Prof Sir Martin Landray, FMedSci; M. Khair ElZarrad, PhD, MPH; Adrian F. Hernandez, MD, MHS)

Rethinking Clinical Trials

The rapidly evolving ecosystem now relies on real-world data, which is becoming increasingly more advanced, and clinical trial design is becoming more complex and innovative. Annex-2 of E6(R3) will include additional considerations of GCP principles focused on decentralized elements, pragmatic elements and real-world data sources.

article thumbnail

Grand Rounds March 24, 2023: From Observational Studies to Pragmatic Clinical Trials: (Almost) A Decade of Research in PCORnet® (Erin Holve, PhD, MPH, MPP; Russell Rothman, MD, MPP; Schuyler Jones, MD; Neha Pagidipati, MD, MPH)

Rethinking Clinical Trials

It has grown to be a major force for supporting pragmatic research, both real-world evidence research and supporting observational research and pragmatic clinical trials. It is an independent, nonprofit, research institute and leading funder of patient-centered comparative clinical effectiveness research (CER).

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

The financial world, like the pharmaceutical industry, must operate within a tightly-defined regulatory environment, and in doing so has proved adept at connecting with its customers. Joanna Carlish, managing director, financial services, Tag Americas. Joanna began her career at Tag as an Account Manager with Banco Santander in London.

article thumbnail

New to ELRIG Drug Discovery 2022: Tech Theatre supported by DDW

Drug Discovery World

Dr Yahya Anvar, Head of Data Science, OKRA.ai She also works on her own research following her PhD in the digitisation of scientific research, smart labs and the lab of the future, and semantic tagging of scientific data, which she has continued as part of the Physical Sciences Data Infrastructure (PSDI) Project.

Drugs 52